Anhui Jiexi Pharm

Anhui Jiexi Pharmaceutical is a clinical-stage biopharmaceutical company headquartered in Hefei, China, specializing in the development of innovative small molecule drugs. The company focuses on therapeutic areas with significant unmet medical needs, including autoimmune diseases, inflammatory conditions, and metabolic disorders. Its pipeline is highlighted by JX-05, a highly selective Janus kinase 1 (JAK1) inhibitor currently in Phase 2 clinical trials for rheumatoid arthritis and atopic dermatitis. Another key program, JX-08, is a potent URAT1 inhibitor being developed for the treatment of gout and hyperuricemia. Anhui Jiexi aims to provide high-quality, affordable innovative medicines through its integrated R&D platform and clinical development expertise.